Long QT Syndrome is a complex cardiac repolarisation disorder associated with a prolonged QT interval and an elevated risk of life-threatening arrhythmias, including torsades de pointes and sudden cardiac arrest. This inherited or acquired condition disrupts the heart’s electrical stability, often linked to mutations in ion-channel genes, electrolyte imbalances or medication effects. As awareness of genetic cardiology and arrhythmia syndromes continues to expand, clinicians increasingly turn to high-quality, evidence-based learning resources and specialised cardiology conference platforms to understand emerging diagnostic tools, risk stratification models and targeted treatment pathways.

The clinical presentation of Long QT Syndrome varies widely—from asymptomatic individuals identified through routine ECGs to patients experiencing syncope, palpitations or malignant ventricular tachyarrhythmias. Early recognition is crucial, particularly in high-risk profiles such as markedly prolonged QT intervals, documented polymorphic VT, family history of sudden death, or pathogenic genetic variants. Risk assessment now includes genotype-phenotype correlation, triggers such as exertion, emotional stress or auditory stimuli, and exposure to QT-prolonging medications.

Because of its strong association with ventricular arrhythmias, management strategies must balance lifestyle modification, trigger avoidance, medication optimisation and decisions about device therapy. Beta-blockers remain first-line therapy for many genotypes, particularly LQT1 and LQT2, due to their effectiveness in suppressing adrenergic-mediated arrhythmias. In selected patients, left cardiac sympathetic denervation offers an additional protective benefit. For those at highest risk, implantable cardioverter-defibrillators (ICDs) reduce mortality but require careful consideration of age, symptom burden, syncope history and tolerance of long-term device care.

This session also explores genetic testing and counselling, which now guide family-based evaluation and help identify silent carriers. Advances in molecular testing, variant classification and precision-medicine approaches continue to refine how clinicians interpret results, counsel families and tailor surveillance strategies. Attendees will gain clarity on how to integrate genetic data into clinical decision-making without creating unnecessary anxiety or overtreatment.

Diagnostic tools such as ECG analysis, exercise stress testing, Holter monitoring and patch monitoring play a central role in identifying concealed LQTS, assessing dynamic QT changes and evaluating therapy response. The programme highlights scenarios where borderline QT intervals require deeper analysis, including measurement techniques, correction formulas and limitations of QTc in tachycardia, bradycardia and autonomic imbalance.

Participants will also examine lifestyle and long-term management considerations. Guidance includes sports participation decisions, medication-avoidance lists, peri-operative precautions, pregnancy considerations and emergency action planning for families and schools. Case discussions show how to approach borderline ECGs, genotype-negative patients and individuals misdiagnosed due to physiological QT prolongation.

Finally, the session reviews future directions such as pharmacogenomics, sodium-channel blockade trials, emerging gene-editing potentials, AI-driven ECG interpretation and innovations in arrhythmia-risk prediction. With a structured understanding of Long QT Syndrome’s mechanisms, risks and treatment options, attendees will be better equipped to counsel patients, design monitoring plans and integrate genetic and electrophysiological insights into their clinical practice.